Tag Archives: ARR

PLEGRIDY? (PEGINTERFERON BETA-1A) APPROVED IN THE EUROPEAN UNION FOR THE TREATMENT OF MULTIPLE SCLEROSIS

PLEGRIDY? (PEGINTERFERON BETA-1A) APPROVED IN THE EUROPEAN UNION FOR THE TREATMENT OF MULTIPLE SCLEROSIS

CAMBRIDGE, Mass. ? July 23, 2014 ? Today Biogen Idec (NASDAQ: BIIB) announced that the European Commission (EC) has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).…

BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

CAMBRIDGE, Mass. and NORTH CHICAGO, Ill. ? June 16, 2014 ? Today Biogen Idec (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular interferon beta-1a (IFN ?-1a),…

BIOGEN IDEC ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF PEGINTERFERON BETA-1A IN MULTIPLE SCLEROSIS

Weston, Mass. ? Jan. 24, 2013 ? Today Biogen Idec (NASDAQ: BIIB) released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE. Results support peginterferon beta-1a as a potential treatment dosed every two weeks or every four weeks for relapsing-remitting multiple sclerosis (RRMS).…
Top